Equine p-tau212 and 214 antibody and antigen (recombinant protein)

 Download 

Product information

Size： 1mg | 10mg | 100mg

Catalog No.	Description	US $ Price (per mg)	First Order Discount	First Order Discount Price
GMP-EQU-p-tau212-214-Ag01	Recombinant Equine p-tau212 and 214 protein	3090
GMP-EQU-p-tau212-214-Ab01	Anti-Equine p-tau212 and 214 mouse monoclonal antibody (mAb)	1953	20%	1562.4
GMP-EQU-p-tau212-214-Ab02	Anti-Equine p-tau212 and 214 mouse monoclonal antibody (mAb)	1953	20%	1562.4
GMP-EQU-p-tau212-214-Ab03	Anti-Equine p-tau212 and 214 mouse monoclonal antibody (mAb)	1953	20%	1562.4
GMP-EQU-p-tau212-214-Ab04	Anti-Equine p-tau212 and 214 mouse monoclonal antibody (mAb)	1953	20%	1562.4

Shipping Costs: $360–$760
Antibodies: $360 Antigens: $760 (Elevated cost due to antigen heterogeneity, post-translational modifications, structural complexity, and specialized handling.)

Product Description

Cat No. of Products	GMP-EQU-p-tau212-214-Ag01
Product Name	Recombinant Equine p-tau212 and 214 protein
Target/Biomarker	Equine Phospho-tau212 and 214 (p-tau212 and 214)
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Equine Phospho-tau212 and 214 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in p-tau212 and 214 level test of animal Equine/Horse with Alzheimer Disease(AD).
Tag	His
Products description	Recombinant Equine p-tau212 and 214 protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No. of Products	GMP-EQU-p-tau212-214-Ab01, GMP-EQU-p-tau212-214-Ab02, GMP-EQU-p-tau212-214-Ab03, GMP-EQU-p-tau212-214-Ab04
Product Name	Anti-Equine p-tau212 and 214 mouse monoclonal antibody (mAb)
Target/Biomarker	Equine Phospho-tau212 and 214 (p-tau212 and 214)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Anti-Equine Phospho-tau212 and 214 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in p-tau212 and 214 level test of animal Equine/Horse with Alzheimer Disease(AD).
Tag	mFc
Products description	Anti-Equine p-tau212 and 214 mouse monoclonal antibody (mAb) was expressed in CHO - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays
Formulation & Reconstitution	Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O.
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Associated products

Target/Biomarker information

Equine p-tau212 and p-tau214 represent a subset of tau proteins specific to the equine neurological landscape. These phosphorylated tau variants are intricately involved in maintaining the structural stability of microtubules within neurons. Under normal circumstances, tau proteins bind to microtubules and aid in their assembly, ensuring proper neuronal function, axonal transport, and synaptic communication. However, the equilibrium in tau phosphorylation is delicate, and when disrupted, it can have far-reaching consequences. In equine neurodegenerative disorders, such as certain tauopathies, aberrant phosphorylation of tau proteins occurs. This post-translational modification leads to tau proteins adopting abnormal conformations, which renders them prone to aggregation. The aggregation of tau proteins culminates in the formation of neurofibrillary tangles, a pathological hallmark reminiscent of similar neurodegenerative diseases in humans, like Alzheimer's disease. Equine p-tau212 and p-tau214, phosphorylated at specific sites within the tau protein sequence, are indicative of this pathological cascade. They serve as early indicators of tauopathy-related neurodegenerative processes in horses. The presence of elevated levels of these biomarkers suggests ongoing tau phosphorylation and the potential emergence of cognitive and neurological deficits in affected equines.

About GDU